At Abington Neurological Associates we are committed to offering cutting edge treatments for our patients. Clinical trials are available in many different areas. Please contact our Clinical Trials Research Office if you are interested in learning more information about any of the trials that we offer at (215) 957-9250.

Additional information about these trials can be found at www.clinicaltrials.gov using the Clinical Trials.gov Identifier code provided after each study title.

Alzheimer's/Mild Cognitive Impairment Studies

  • A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for theTreatment of Agitation in Patients with Dementia of the Alzheimer’s Type ID# NCT02446132
  • A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis. ID# NCT03325556
  • A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, and Safety Study of MTAU9937A in Patients with Prodromal to Mild Alzheimer's Disease. ID# NCT03289143
  • A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease. ID# NCT03444870
  • A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Study Comparing up to 1400mg of LY3002813 Alone and in Combination With 12mg of LY3202626 With Placebo Over 80 Weeks in Approximately 300 Patients With Early Symptomatic Alzheimer's Disease ID# NCT03367403
  • A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease. ID# NCT03131453
  • A Randomized, Double-Blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease. ID# NCT02565511
  • Escitalopram for Agitation in Alzheimer's Disease (SCITAD). ID# NCT03108846

Stroke - TIA Studies

Parkinson's Disease Studies

Multiple Sclerosis Studies

  • A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). ID# NCT02047097
  • Long-term, Prospective, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy ID# NCT01442194
  • A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies. ID# NCT03222973

Chronic Regional Pain Syndrome

Headache/Migraine Trials